L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) – a single-arm phase II study

Karen J Maddox; Eva González Barca; Wojciech Jurczak; Anna Maria Liberati; Johannes Düvel; Zsolt Nagy; Tomáš Papák; Mark Andreu; Nagore Kalieka; Martin H Dreyling; Pier Luigi Zinzani; Sunmeet Yip; Ambarkhane; Johannes Weiseth; Gilles A Safran

ASCO June 2–6, 2017: Abstract 7514

CD19 is a broadly and homogeneously expressed antigen on B-cell malignancies including DLBCL, and enhances Fc receptor (FcR) signaling and tumor cell proliferation.1,2,3 MOR208 is a fully-humanized, monoclonal antibody that targets CD19 on tumor cells, leading to tumor-ligand (Fc) cell-mediated antibody-dependent cell-mediated cytotoxicity, macrophage-mediated antibody-dependent-cell-mediated phagocytosis and direct cytolysis (Figure 1).

**Methods**

**Patients**

**Key inclusion criteria**
- Patients with a primary refractory diffuse large B-cell lymphoma (DLBCL), history of previously treated DLBCL, and those with central nervous system involvement are excluded.

**Key exclusion criteria**
- Patients with grade 3 or 4 labile lymphoma, or histological transformation from indolent lymphoma/BDCL, with subsequent relapse are also excluded.

**Study design**
- Phase I, single-arm, open-label, multicenter study (NCT01399583, Figure 2).
- The enrollment of 80 patients is planned; recruitment is ongoing.

**Objectives**

Discussion of results: MOR208 and LEN modes of action

**Results**

This is a report of preliminary efficacy (investigator assessed, according to the revised response criteria based on the guidelines of International Working Group, reported by Cheson et al3) and safety data.

**Conclusions**

MOR208 in combination with LEN was well tolerated, 27% patients required a reduction of LEN dose due to toxicity.

**References**


**Disclosures**

This study was sponsored by MorphoSys AG. Medical writing support was provided by Jim Heighway PhD, Cancer Communications, and was funded by MorphoSys AG. This study was presented at the ASCO 2017 meeting (Abstract 7514).